MX2022014958A - Composiciones y métodos para tratar el síndrome de dificultad respiratoria aguda (sdra) y trastornos inflamatorios provocados por coronavirus y otros patógenos respiratorios o agentes que median en la lesión pulmonar, inflamación dificultad respiratoria aguda, asi como composiciones y métodos relacionados para tratar y prevenir la infección por coronavirus sars en humanos, la enfermedad por covid-19 y síntomas relacionados. - Google Patents
Composiciones y métodos para tratar el síndrome de dificultad respiratoria aguda (sdra) y trastornos inflamatorios provocados por coronavirus y otros patógenos respiratorios o agentes que median en la lesión pulmonar, inflamación dificultad respiratoria aguda, asi como composiciones y métodos relacionados para tratar y prevenir la infección por coronavirus sars en humanos, la enfermedad por covid-19 y síntomas relacionados.Info
- Publication number
- MX2022014958A MX2022014958A MX2022014958A MX2022014958A MX2022014958A MX 2022014958 A MX2022014958 A MX 2022014958A MX 2022014958 A MX2022014958 A MX 2022014958A MX 2022014958 A MX2022014958 A MX 2022014958A MX 2022014958 A MX2022014958 A MX 2022014958A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- acute respiratory
- ards
- respiratory distress
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 title abstract 2
- 241000711573 Coronaviridae Species 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 208000025721 COVID-19 Diseases 0.000 abstract 2
- 230000001154 acute effect Effects 0.000 abstract 2
- 206010052015 cytokine release syndrome Diseases 0.000 abstract 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 abstract 2
- 239000002644 phorbol ester Substances 0.000 abstract 2
- 241001678559 COVID-19 virus Species 0.000 abstract 1
- 208000001528 Coronaviridae Infections Diseases 0.000 abstract 1
- 208000037847 SARS-CoV-2-infection Diseases 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 150000004633 phorbol derivatives Chemical class 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
- C07C69/33—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with hydroxy compounds having more than three hydroxy groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se proporcionan métodos y composiciones que contienen un éster de forbol o un derivado de un éster de forbol para la prevención y el tratamiento de una infección por coronavirus del síndrome respiratorio agudo grave (SARS), incluyendo la infección por SARS-CoV-2 y la enfermedad por COVID-19 relacionada. Asimismo, se proporcionan métodos y composiciones para prevenir y tratar afecciones inflamatorias agudas y lesiones patógenas relacionadas, que incluyen el síndrome de dificultad respiratoria aguda (SDRA) y el síndrome de tormenta de citocinas (CSS) observados en casos graves de SARS-CoV-2/COVID-19.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063031551P | 2020-05-28 | 2020-05-28 | |
| PCT/US2021/034494 WO2021243007A2 (en) | 2020-05-28 | 2021-05-27 | Compositions and methods for treating acute respiratory distress syndrome (ards) and inflammatory disorders caused by coronaviruses and other respiratory pathogens or agents that mediate pulmonary injury, inflammation or acute respiratory distress, and related compositions and methods for treating and preventing human sars coronavirus infection, covid-19 disease and related symptoms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022014958A true MX2022014958A (es) | 2023-04-13 |
Family
ID=78722786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022014958A MX2022014958A (es) | 2020-05-28 | 2021-05-27 | Composiciones y métodos para tratar el síndrome de dificultad respiratoria aguda (sdra) y trastornos inflamatorios provocados por coronavirus y otros patógenos respiratorios o agentes que median en la lesión pulmonar, inflamación dificultad respiratoria aguda, asi como composiciones y métodos relacionados para tratar y prevenir la infección por coronavirus sars en humanos, la enfermedad por covid-19 y síntomas relacionados. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20230248684A1 (es) |
| EP (1) | EP4304570A2 (es) |
| JP (1) | JP2023528804A (es) |
| KR (1) | KR20230058014A (es) |
| CN (1) | CN117015375A (es) |
| AU (1) | AU2021281257A1 (es) |
| BR (1) | BR112022024226A2 (es) |
| CA (1) | CA3180577A1 (es) |
| CL (1) | CL2022003348A1 (es) |
| IL (1) | IL298593A (es) |
| MX (1) | MX2022014958A (es) |
| WO (1) | WO2021243007A2 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021190553A1 (zh) * | 2020-03-27 | 2021-09-30 | 中山康方生物医药有限公司 | 抗IL-1β的抗体、其药物组合物及其用途 |
| CN115252760B (zh) * | 2022-03-30 | 2024-05-31 | 厦门大学 | 一种广谱抗冠状病毒的制剂及其制备方法 |
| CN117919385B (zh) * | 2024-02-05 | 2024-10-18 | 中国医学科学院医学实验动物研究所 | IL-37在MERS-CoV感染疾病的治疗中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101374760B1 (ko) * | 2011-10-26 | 2014-03-17 | 한국생명공학연구원 | 포볼 타입의 디테르펜 화합물 및 이를 포함하는 바이러스 감염 질환의 치료 또는 예방용 약학적 조성물 |
| WO2019108456A1 (en) * | 2017-12-01 | 2019-06-06 | Children's Hospital Medical Center | Compositions for interferon blockade and methods of using same |
-
2021
- 2021-05-27 AU AU2021281257A patent/AU2021281257A1/en active Pending
- 2021-05-27 EP EP21812442.8A patent/EP4304570A2/en active Pending
- 2021-05-27 MX MX2022014958A patent/MX2022014958A/es unknown
- 2021-05-27 KR KR1020227045667A patent/KR20230058014A/ko active Search and Examination
- 2021-05-27 BR BR112022024226A patent/BR112022024226A2/pt not_active Application Discontinuation
- 2021-05-27 WO PCT/US2021/034494 patent/WO2021243007A2/en active Application Filing
- 2021-05-27 US US17/928,235 patent/US20230248684A1/en not_active Abandoned
- 2021-05-27 CA CA3180577A patent/CA3180577A1/en active Pending
- 2021-05-27 JP JP2022573211A patent/JP2023528804A/ja active Pending
- 2021-05-27 CN CN202180059368.3A patent/CN117015375A/zh active Pending
- 2021-05-27 IL IL298593A patent/IL298593A/en unknown
-
2022
- 2022-11-28 CL CL2022003348A patent/CL2022003348A1/es unknown
-
2023
- 2023-11-10 US US18/388,597 patent/US20240082202A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023528804A (ja) | 2023-07-06 |
| WO2021243007A3 (en) | 2021-12-30 |
| KR20230058014A (ko) | 2023-05-02 |
| EP4304570A2 (en) | 2024-01-17 |
| US20240082202A1 (en) | 2024-03-14 |
| US20230248684A1 (en) | 2023-08-10 |
| IL298593A (en) | 2023-01-01 |
| BR112022024226A2 (pt) | 2023-01-31 |
| AU2021281257A1 (en) | 2023-02-02 |
| CN117015375A (zh) | 2023-11-07 |
| WO2021243007A2 (en) | 2021-12-02 |
| CL2022003348A1 (es) | 2023-12-01 |
| CA3180577A1 (en) | 2021-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022014958A (es) | Composiciones y métodos para tratar el síndrome de dificultad respiratoria aguda (sdra) y trastornos inflamatorios provocados por coronavirus y otros patógenos respiratorios o agentes que median en la lesión pulmonar, inflamación dificultad respiratoria aguda, asi como composiciones y métodos relacionados para tratar y prevenir la infección por coronavirus sars en humanos, la enfermedad por covid-19 y síntomas relacionados. | |
| JOP20220179A1 (ar) | N4-هيدروكسي سيتيدين ومشتقات واستخدامات مضادة للفيروسات مرتبطة بها | |
| UA89791C2 (ru) | Пищевая композиция, которая содержит неусваиваемые олигосахариды, для лечения или профилактики инфекций респираторного тракта | |
| NO20056073L (no) | Sammensetninger og fremgangsmater til behandling av alvorlig akutt respitatorisk syndrom (SARS) | |
| NO20060977L (no) | Mitokinon-derivater anvendt som mitokondrielle malsokende antioksidanter | |
| BRPI0518655A2 (pt) | composiÇço oral para o tratamento, inibiÇço ou reduÇço de uma condiÇço inflamatària oral, mÉtodo de pelo menos um dentre tratar e inibir uma condiÇço inflamatària oral, composiÇço de cuidado oral, e, mÉtodo de pelo menos um dentre tratar e inibir uma condiÇço inflamatària oral e prover atividade antioxidante em uma cavidade oral | |
| MX2022013749A (es) | Metodos y composiciones para el tratamiento del coronavirus 2 del sindrome respiratorio agudo severo (sars-cov-2). | |
| MX2022001337A (es) | Uso de cannabidiol en el tratamiento del sindrome de dravet. | |
| MX2022013081A (es) | Compuestos para el tratamiento de sars. | |
| MX2021008702A (es) | Uso de cannabinoides en el tratamiento de las comorbilidades asociadas a la epilepsia. | |
| ES2180936T3 (es) | Nuevos derivados de iridoide e inhibidores de la neovascularizacion que tienen como ingrediente activo dichos derivados. | |
| MX2022011697A (es) | Inhibidores de ciclofilina y usos de los mismos. | |
| MX2022014199A (es) | Usos y formulaciones de los cannabinoides. | |
| MX2022012923A (es) | Inhibidores de trpc6 para tratar afecciones respiratorias. | |
| MX2022010960A (es) | Métodos y composiciones para tratar el trastorno por uso de cannabis y mitigar la abstinencia de cannabinoides. | |
| MX2024000043A (es) | Compuestos inhibidores de la caspasa-2. | |
| WO2004058329A3 (en) | Ester combination local anesthetic | |
| MX2022013722A (es) | Cisteamina para el tratamiento de infección por sars-cov-2. | |
| MX2024003665A (es) | Composición y metodo para la prevención y el tratamiento de lesión cutánea por radiación. | |
| MX2023000154A (es) | Inhibidores de la esfingomielinasa acida para prevenir y tratar la enfermedad covid-19. | |
| MX2023014704A (es) | Inhibidores de proteasa para el tratamiento de infecciones por coronavirus. | |
| MX2023003725A (es) | Composiciones farmacéuticas y usos de las mismas para la prevención y/o tratamiento de la inflamación. | |
| WO2022065970A3 (ko) | 천연물 혼합 추출물을 포함하는 코로나바이러스 감염 예방 또는 치료용 조성물 | |
| EP3939585A4 (en) | PREVENTIVE OR THERAPEUTIC COMPOSITION FOR INFECTIOUS DISEASES WITH SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 | |
| WO2024086777A3 (en) | Compounds and methods for treating diseases caused by viruses and bacteria |